Faculty scientists have made an important discovery in skin cancer treatments. They found that the HIV drug Nelfinavir can help treatments of melanoma to become more potent.
Skin cancer is a major problem in the UK, with more than 13,000 people being diagnosed with melanomas every year and over 2,000 people dying from it. There are drugs that are available to help treat melanoma skin cancer, but these can be ineffective because melanoma cells become resistant to them over time. After the resistance, the cells go on to make genetic changes which make it extremely hard to attack them.
Professor Claudia Wellbrock and her team found that Nelfinavir can help prevent cancer cells from becoming resistant to the treatment, making the cancer fighting agents more effective for a longer time.
The team discovered that cancer cells were able to rewire themselves by using a molecular change. This change that typically takes place in the first two weeks of cancer treatments, helps the cancer cells to develop resistance.
It was this molecular change that Wellbrock targeted by the use of Nelfinavir. It was found that Nelfinavir actually blocks the cells from rewiring and they were therefore less likely to develop resistance to the cancer treatment.
It is now thought that Nelfinavir could be administrated alongside existing cancer drugs in order to improve their effectiveness and boost the patient’s chances of survival.
Professor Wellbrock says:
“In the first few weeks of standard treatment for skin cancer, the cancer cells become stronger and more robust against treatment. But if we can target skin cancer cells before they become fully resistant, we would have a much better chance of blocking their escape. We think this research has brought us one step closer to making this a reality.”
The paper can be found at Cancer Cell http://www.cell.com/cancer-cell/fulltext/S1535-6108(16)30037-X